在 B 细胞惰性 NHL 或 CLL 患者中输注自体、Blinatumomab 扩增 T 细胞（BET）后迅速免疫重建。

1

Blood Cancer J. 2024 Apr 26;14(1):73. doi: 10.1038/s41408-024-01057-z.

2

J Immunol. 2014 Nov 1;193(9):4739-47. doi: 10.4049/jimmunol.1401550. Epub 2014 Sep 29.

3

Haematologica. 2013 Dec;98(12):1930-8. doi: 10.3324/haematol.2012.082248. Epub 2013 Jun 28.

4

Clin Cancer Res. 2021 Mar 15;27(6):1744-1755. doi: 10.1158/1078-0432.CCR-20-4576. Epub 2021 Jan 15.

5

Blood. 2021 Nov 11;138(19):1843-1854. doi: 10.1182/blood.2020009686.

6

Blood. 2018 Aug 2;132(5):521-532. doi: 10.1182/blood-2018-02-830992. Epub 2018 May 9.

7

J Clin Oncol. 2016 Apr 1;34(10):1104-11. doi: 10.1200/JCO.2014.59.1586. Epub 2016 Feb 16.

8

JCI Insight. 2019 Apr 2;5(9):122627. doi: 10.1172/jci.insight.122627.

9

Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005.

10

Semin Hematol. 2024 Apr;61(2):119-130. doi: 10.1053/j.seminhematol.2024.01.001. Epub 2024 Jan 5.

Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL.